Last reviewed · How we verify
Dexmedetomidine 0.75 microgram/kg
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of initially intubated and mechanically ventilated patients in intensive care units, Procedural sedation and analgesia, Perioperative anxiolysis and analgesia.
At a glance
| Generic name | Dexmedetomidine 0.75 microgram/kg |
|---|---|
| Sponsor | Sindh Institute of Urology and Transplantation |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for sedation in intensive care settings and procedural sedation.
Approved indications
- Sedation of initially intubated and mechanically ventilated patients in intensive care units
- Procedural sedation and analgesia
- Perioperative anxiolysis and analgesia
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Tachycardia (rebound)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: